← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
FISCHER JOST
Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001366841
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 0
- Purchases · 24M
- 2
- Average purchase
- $42.5K
- Median purchase
- $42.5K
- Gross purchase value
- $85.0K
Companies: AEON Biopharma, Inc.
2 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2025-05-23 | AEON Biopharma, Inc. | AEON | Director | $29.4K | Open filing |
| 2025-05-21 | AEON Biopharma, Inc. | AEON | Director | $55.6K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 2Small Sample | 100.0% (2/2) | 100.0% (2/2) | +11.7% | +11.7% | +0.8% |
| 20D | 2Small Sample | 100.0% (2/2) | 100.0% (2/2) | +39.2% | +39.2% | +27.5% |
| 60D | 2Small Sample | 100.0% (2/2) | 100.0% (2/2) | +32.1% | +32.1% | +19.4% |
| 120D | 2Small Sample | 100.0% (2/2) | 100.0% (2/2) | +66.6% | +66.6% | +59.3% |
Research patterns
- First purchase in 12M
- 0/1
- Large purchase ≥ $100k
- 0/2
- Cluster buying · 15D
- 0/2
- Buying the dip
- 2/2
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.